Okay. Good afternoon, everybody. Thank you for joining us. I'm Doug Tsao, Senior Analyst at H.C. Wainwright. We are thrilled today for what I think is a very unique event. We are joined by Professor ...
Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...
Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. After brushing off a recommendation to end a phase 3 study earlier this year based on ...
Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary ...
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
The Brief keeps Texas voters and political observers up to speed on the most essential coverage of their elected officials, the policies that shape their daily lives and the future of our great state.
Proponents of the theory and praxis of social ecology the holistic approach to reharmonizing society and nature originated by social theorist Murray Bookchin during the 1960s ’90s have long sought new ...
Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...
CLEVELAND — There’s a new place to grab a bite to eat at Playhouse Square in downtown Cleveland: Welcome to Something Good Social Kitchen. This new spot, which you’ll find at a kiosk on the Playhouse ...
Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) on Wednesday, citing the potential of its epilepsy franchise. Analyst Rudy Li writes, “Epilepsy remains one of our ...
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback